• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经尿道切除术后浅表性膀胱癌复发相关因素分析

[An analysis of factors related to recurrence of superficial bladder cancer after transurethral resection].

作者信息

Tashiro K, Nakajo H, Iwamuro S, Furuta A, Iwanaga S, Ohishi Y, Igarashi H, Kawashima A, Sugiyama K, Kido A

机构信息

Department of Urology, Atsugi Prefectural Hospital.

出版信息

Nihon Hinyokika Gakkai Zasshi. 1995 Jul;86(7):1272-8. doi: 10.5980/jpnjurol1989.86.1272.

DOI:10.5980/jpnjurol1989.86.1272
PMID:7637244
Abstract

A total of 205 patients with primary superficial bladder cancer (Ta, T1) followed more than 3 years were retrospectively analyzed for factors related to recurrence of tumors after transurethral resection. Patients age were 25 to 90 years old, average 61 years old, and there were 160 males and 45 females. Initial tumor grades were G0 in 4 patients, G1 in 48, G2 in 134 and G3 in 19. Seventy four patients had Ta tumor and 131 had T1. Initial treatments were transurethral resection (TUR) alone in 137 patients. TUR with intravesical chemotherapy in 64, with BCG therapy in 7 and others in 7. Factors examined included age, sex, chief complaint, shape, size, and number of tumors, tumor distribution (single area or multiple area), histological grade, stage and intravesical chemotherapy. Overall non-recurrent rate were 81.7% at 1 year, 60.7% at 3 year, 53. 8% at 5 year and 44.2% at 8 year. Five-year non-recurrent rate according tumor factors, showed significant difference regarding tumor size (< 1 cm or 1 cm <: P = 0.027), tumor number (single or multiple: P = 0.004), tumor distribution (single area or multiple area: p = 0.002), histological grade (< G1 or G2 < : p = 0.001) and stage (Ta or T1: p = 0001). However, there were no significant difference regarding factors of age, sex, chief complaint, tumor figure and presence or absence of intravesical chemotherapy. This results suggested that the tumor factors of size, number, tumor distribution, grade and stage were highly related to intravesical tumor recurrence of superficial bladder cancer.

摘要

对205例原发性浅表性膀胱癌(Ta、T1期)且随访超过3年的患者进行回顾性分析,以探讨经尿道切除术后肿瘤复发的相关因素。患者年龄为25至90岁,平均61岁,其中男性160例,女性45例。初始肿瘤分级:G0级4例,G1级48例,G2级134例,G3级19例。Ta期肿瘤74例,T1期肿瘤131例。初始治疗:137例患者仅行经尿道切除术(TUR);64例行TUR联合膀胱内化疗;7例行TUR联合卡介苗治疗;7例为其他治疗。研究因素包括年龄、性别、主诉、肿瘤形状、大小、数量、肿瘤分布(单区域或多区域)、组织学分级、分期及膀胱内化疗。1年时总体无复发率为81.7%,3年时为60.7%,5年时为53.8%,8年时为44.2%。根据肿瘤因素得出的5年无复发率在肿瘤大小(<1 cm或≥1 cm:P = 0.027)、肿瘤数量(单发或多发:P = 0.004)、肿瘤分布(单区域或多区域:P = 0.002)、组织学分级(<G1或≥G2:P = 0.001)及分期(Ta或T1:P = 0.001)方面显示出显著差异。然而,在年龄、性别、主诉、肿瘤形态及是否进行膀胱内化疗等因素方面无显著差异。该结果表明,肿瘤的大小、数量、分布、分级及分期等因素与浅表性膀胱癌的膀胱内肿瘤复发高度相关。

相似文献

1
[An analysis of factors related to recurrence of superficial bladder cancer after transurethral resection].经尿道切除术后浅表性膀胱癌复发相关因素分析
Nihon Hinyokika Gakkai Zasshi. 1995 Jul;86(7):1272-8. doi: 10.5980/jpnjurol1989.86.1272.
2
Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
Jpn J Clin Oncol. 2002 Nov;32(11):461-5. doi: 10.1093/jjco/hyf103.
3
The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?浅表性膀胱肿瘤的最佳治疗方法:单纯经尿道膀胱肿瘤切除术与经尿道膀胱肿瘤切除术联合膀胱内化疗方式的比较?
Int Urol Nephrol. 2000;32(1):53-8. doi: 10.1023/a:1007199932271.
4
Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.无原位癌伴发的膀胱浅表性移行细胞癌膀胱内复发预测因素分析
Int J Urol. 2006 Nov;13(11):1389-92. doi: 10.1111/j.1442-2042.2006.01562.x.
5
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
6
Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.浅表性膀胱癌经尿道切除术、二次探查切除术及长期化疗预防的回顾性分析:差异化治疗方法的适应证及疗效
J Endourol. 2007 Dec;21(12):1533-41. doi: 10.1089/end.2007.9866.
7
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.初次诊断为高级别T1期后再次经尿道切除术时仍为高级别T1期,其肿瘤学预后较差:一项多机构研究的结果
Urol Int. 2018;101(1):7-15. doi: 10.1159/000490765. Epub 2018 Jul 4.
8
Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.经尿道切除浅表性膀胱癌后卡介苗的免疫预防性膀胱内应用。
Croat Med J. 2003 Apr;44(2):187-92.
9
Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.T1 期高级别膀胱癌患者在二次 TUR 时代发生膀胱内复发的危险因素。
Jpn J Clin Oncol. 2013 Apr;43(4):404-9. doi: 10.1093/jjco/hyt016. Epub 2013 Feb 26.
10
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.膀胱T1期肿瘤患者接受膀胱内丝裂霉素治疗后重复经尿道切除术对复发率和进展率的影响:一项前瞻性随机临床试验。
J Urol. 2006 May;175(5):1641-4. doi: 10.1016/S0022-5347(05)01002-5.